TNFRSF18 and neoplasm: Though single-agent anti-Gal-9 (RG9-1) showed only modest effects in mice bearing EMT-6 breast or MC-38 colon adenocarcinoma tumors, its combined treatment with a blocking ab (DTA-1) against the glucocorticoid-induced TNFR-related protein (GITR) stimulated T cell activation, decreased tumor growth, and increased survival relative to monotherapy [5].